For research use only.

Catalog No.S7362

6 publications

AZD5582 Chemical Structure

CAS No. 1258392-53-8

AZD5582, a novel small-molecule IAP inhibitor, binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP with IC50 values of 15, 21, and 15

Selleck's AZD5582 has been cited by 6 publications

Purity & Quality Control

Choose Selective IAP Inhibitors

Biological Activity

Description AZD5582, a novel small-molecule IAP inhibitor, binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP with IC50 values of 15, 21, and 15
cIAP1 [1]
(Cell-free assay)
XIAP [1]
(Cell-free assay)
cIAP2 [1]
(Cell-free assay)
15 nM 15 nM 21 nM
In vitro

Human pancreatic cancer cells display different sensitivities to the synthetic IAP antagonist, AZD5582. Treating human pancreatic cancer cells with AZD5582 differentially induces apoptosis, dependent on the expression of p-Akt and p-XIAP. It targets cIAP1 to induce TNF-α-induced apoptosis. AZD5582 induces a decrease of Mcl-1 protein, a member of the Bcl-2 family, but not that of Bcl-2 and Bcl-xL[1]. HNSCC (head and neck squamous cell carcinoma) cell lines SCC25, Cal27, and FaDu show a dose-dependent cytotoxic effect after treatment with AZD5582[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 MoL6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M1HsXFQ5KGi{cx?= MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KEGuYX3hdkBDdHWnIHHzd4F6NCCJSUWwJF0hOC5yMECwOkDPxE1w MmHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkC5PVgoRjJ2M{KwPVk5RC:jPh?=
MDA-MB-231 NITDc4dHfW6ldHnvckBie3OjeR?= MkXINUBpeg>? Ml7pRolv\GmwZzDh[oZqdmm2eTD0c{BkUUGSMTDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCycn;0[YlvKGSnZ4Lh[IF1cW:wIHHmeIVzKDFiaIKgZpkhTUyLU1GsJGVEPTBiPTCwMlAxODFizszNMi=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{MEm5PEc,OjR|MkC5PVg9N2F-
MDA-MB-231 NH\2[HJCeG:ydH;zbZMh[XO|YYm= MYCwMlUhfG9iMT61JI5O MWKxJJRwKDNiaILz MWHJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiY3HzdIF{\S1|IHPs[YF3[WenIHH0JFAvPSC2bzCxMlUhdk1icILlbY5kfWKjdHXkJIZweiBzIITvJFMhcHK|IH\vcIxwf2WmIHL5JINwdXCxdX7kMZdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkC5PVgoRjJ2M{KwPVk5RC:jPh?=
MDA-MB-231 NED0OZpCdnSrdIXtc5Ih[XO|YYm= NUfHdYdSOC5zIITvJFMhdWdxa3e= MlX6NkB4\WWtcx?= M{C0cmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNieHXuc4dz[W[2ZXSgbY4hS0JzNzDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMTD0c{A{KG2pL3vnMEBqfiCjZH3pcol{fGW{ZXSgc45k\SCjIIfl[Ysh\m:{IEKge4Vmc3NibXXhd5Vz\WRidIfpZ4Uh[SC5ZXXrJIZweiB5ODDkZZl{ MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{MEm5PEc,OjR|MkC5PVg9N2F-
MDA-MB-231 NHPiZ|dHfW6ldHnvckBie3OjeR?= NYridnBKOC5yNTD0c{A{KG2pL3vn MWO0JJRwKDF6IHjydy=> NHTCeWxKdmS3Y4Tpc44hd2ZiY3HzdIF{\S1|IHPs[YF3[WenIHnuJJR2dW:{IH;mJGNDOTdiU1PJSEBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMD6wOUB1dyB|IH3nM4toNCCrdjDh[pRmeiB2IITvJFE5KGi{czDifUBGVEmVQR?= M4XIOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{KwPVk5Lz5{NEOyNFk6QDxxYU6=
MDA-MB-231 NX76UVVqTnWwY4Tpc44h[XO|YYm= MkjSNE4xPSC2bzCzJI1oN2up NGXGcJR2eCC2bzCxPEBpenN? MV\JcoR2[3Srb36gc4Yh[0mDUEGg[IVoemGmYYTpc44hcW5idIXtc5Ihd2ZiQ1KxO{BUS0mGIH3veZNmKHinbn;ndoFnfGWmIIfpeIghcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDheEAxNjB3IITvJFMhdWdxa3esJIl3KHWyIITvJFE5KGi{czDifUBGVEmVQR?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{MEm5PEc,OjR|MkC5PVg9N2F-
BT549 NXfDXpB[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4n3e2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGJVPTR7IHPlcIx{ M2no[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{KwPVk5Lz5{NEOyNFk6QDxxYU6=
MDA-MB-231 NXjmfZZrSXCxcITvd4l{KGG|c3H5 NFL1ZXYxNjVidH:gNU42KG6P M2TqO|EhfG9iMzDodpM> Mnm0TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwh\GWjdHigZZQhOC53IITvJFEvPSCwTTDwdoVqdmO3YnH0[YQh\m:{IEGgeI8hOyCqcoOg[o9tdG:5ZXSgZpkh[2:vcH;1coQuf2G|aH;1eEBu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5 MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{MEm5PEc,OjR|MkC5PVg9N2F-
MDA-MB-231 NVToblZnTnWwY4Tpc44h[XO|YYm= NUm5dXRNOSC3TR?= M1TxXlQhcHK| NXrMbIdjUW6qaXLpeIlwdiCxZjDYTWFRNWOjc4Dhd4UuQSCrboTldoFkfGmxbjDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHH0JFEhfU1iYX\0[ZIhPCCqcoOgZpkhcW2vdX7vdJJm[2myaYTheIlwdiCjc4PhfS=> M1vTeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{KwPVk5Lz5{NEOyNFk6QDxxYU6=
MDA-MB-231 M1n6TWZ2dmO2aX;uJIF{e2G7 NWHLc3ljOC5yMzD0c{AyKG6P MVOxJIhz NVnKSm85SmmwZHnu[{Bi\m[rbnn0fUB1dyClSVHQNkBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDwdo91\WmwIHTl[5Ji\GG2aX;uJIF1KDBwMEOgeI8hOSCwTTDh[pRmeiBzIHjyJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> NHrYbWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyNFk6QCd-MkSzNlA6QTh:L3G+
647V M2juPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjC2OFdXKGOnbHzz MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{MEm5PEc,OjR|MkC5PVg9N2F-
35612 MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjC5O{04KGOnbHzz MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{MEm5PEc,OjR|MkC5PVg9N2F-
MIAPaCa2 NYPIN4VDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmfmS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWlCWGGFYUKgZ4VtdHN? MkLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|MkC5PVgoRjJ2M{KwPVk5RC:jPh?=

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot

PubMed: 26314849     

BxPC-3, Capan-2 (upper panel), Panc-1 and AsPC-1 (lower panel) were treated with the indicated doses of AZD5582 and the cell lysates were then immunoblotted using XIAP and γ-tubulin antibodies. γ-tubulin was used as a loading control.

In vivo After AZD5582 treatment, tumor growth and weight decrease, whereas cleaved caspase 3 expression increases in Panc-1-derived xenograft model[1]. When administered intravenously to MDA-MB-231 xenograft-bearing mice, AZD5582 results in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg. Following a modest 0.5 mg/kg intravenous bolus dose of AZD5582 in mice, unbound plasma levels remain above the concentrations at which apoptosis induction and cell death are observed in MDA-MB-231 cells over the course of several hours. Although cIAP1 degradation happens very quickly upon exposure to AZD5582 in vivo, apoptosis induction (as measured by the amount of cleaved caspase-3) takes longer to reach a maximal effect. A single agent AZD5582 does not exhibit broad-based cytotoxicity but instead should be employed in selected tumor settings expected to be sensitive to IAP inhibitors or in rational combinations with other targeted therapies. The dihydrochloride salt of AZD5582 has sufficient aqueous solubility (>7 mg/mL at pH 4−6) to enable formulation for intravenous administration at the projected efficacious doses. With respect to chemical stability, AZD5582 is found to be photostable and hydrolytically stable between pH 4−6, although some amide hydrolysis is observed under strongly acidic (pH < 1) and basic (pH > 8) conditions. In addition, the compound is stable in the plasma of multiple species, with no compound degradation observed after several hours under physiological conditions[3].


Cell Research:


- Collapse
  • Cell lines: The human pancreatic cancer cell lines including BxPC-3, Miapaca-2, Panc-1, Panc0813, PL45, Capan-1, Capan-2 and AsPC-1
  • Concentrations: 0, 0.01, 0.1, 0.5 μM
  • Incubation Time: 72 h
  • Method:

    DNA or siRNA-transfected or AZD5582-treated cells are collected and cell death is determined by trypan blue exclusion using at least 200∼500 cells. For the MTS assay, pancreatic cancer cells are seeded at 1∼3 × 104 cells/well in a 96-well microtiter plate. The following day, cells are treated with AZD5582, an IAP antagonist, with various doses for 72 h. The MTS assay is performed according to the MTS assay protocol 

    (Only for Reference)
Animal Research:


- Collapse
  • Animal Models: Xenograft tumor (in Balb/c nude mice)
  • Dosages: 3 mg/kg
  • Administration: i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 100 mg/mL (98.49 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1015.29


CAS No. 1258392-53-8
Storage powder
in solvent
Synonyms N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IAP Signaling Pathway Map

Tags: buy AZD5582|AZD5582 ic50|AZD5582 price|AZD5582 cost|AZD5582 solubility dmso|AZD5582 purchase|AZD5582 manufacturer|AZD5582 research buy|AZD5582 order|AZD5582 mouse|AZD5582 chemical structure|AZD5582 mw|AZD5582 molecular weight|AZD5582 datasheet|AZD5582 supplier|AZD5582 in vitro|AZD5582 cell line|AZD5582 concentration|AZD5582 nmr|AZD5582 in vivo|AZD5582 clinical trial|AZD5582 inhibitor|AZD5582 Apoptosis inhibitor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID